Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

ELUT

SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.

Institutional investors interested in meeting with management during the conference may reach out to their Canaccord representative.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com


Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today